Direct: (510) 463-0133 lcraft@onpointanalytics.com

Phone: (510) 463-0130

Fax: (510) 463-0131

Senior Consultant

OnPoint Analytics

Laura Craft is a co-founder of OnPoint Analytics and served as its President from 2004 through 2024. She has a Master's of Public Health degree from the University of California at Berkeley and heads up the firm's healthcare practice. For more than twenty years her work has focused on health care costs, insurance, and reimbursement practices. In addition to other health care products and services, Ms. Craft has worked on more than 65 litigations involving prescription drugs, focusing on pricing practices, PBM and other intermediary participation, formularies, cost sharing and government contributions. She works on a daily basis with electronic data systems for prescription drug dispensing and payment, as well as the regulatory and commercial requirements that inform them.

Beyond healthcare, Ms. Craft has been responsible for coordinating nationwide class action litigation, supporting billions of dollars of troubled debt portfolio run off, implementing strategies to assure recovery from failing financial institutions, designing products to facilitate safe and more efficient over-the-counter trading of complex derivatives, and lobbying or providing comments to Congress on multiple questions of regulatory reform. Her experience provides her with a comprehensive perspective on the legal process and the unique role filled by the testifying expert.

PUBLICATIONS

Empirical Challenges in Pharma Litigation, Craft, Kovach, Wallace and Cortez (2017)

TEACHING

Instructor for Continuing Legal Education programs certified in major jurisdictions throughout the U.S. involving:

- Emerging antitrust issues in pharmaceuticals and life sciences sectors
- Data and empirical issues in pharmaceutical litigation
- Antitrust claims involving pharmaceutical products
- Estimation of intellectual property damages

EDUCATION

University of California, Berkeley Master of Public Health

University of California, Hastings College of the Law *Juris Doctor (J.D.)*

University of California, Los Angeles Bachelor of Arts (B.A.)

EXPERT TESTIMONY 2021 - 2025

In re: Generic Pharmaceuticals Pricing Litigation Fine, Kaplan and Black, R.P.C. (2022–)

• Expert Reports, Deposition and Hearing Testimony

GEHA v. Actelion Pharmaceuticals (Tracleer)
Cohen Milstein Sellers & Toll PLLC (2022–)

• Expert Report, Deposition Testimony

In re: Actos End-Payor Antitrust Litigation
Cohen Milstein Sellers & Toll PLLC (2023–)

• Expert Reports, Deposition and Hearing Testimony

United States of America ex rel. Sarah Behnke v. CVS Caremark Corporation, et al. Berger Montague (2022–)

• Expert Reports, Deposition Testimony

In re: Xyrem (Sodium Oxybate) Antitrust Litigation Girard Sharp (2022–)

• Expert Report, Deposition Testimony

In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation Cohen Milstein Sellers & Toll PLLC (2023–2024)

• Expert Reports, Deposition Testimony

MSP Recovery Claims, Series LLC, et al. v. Express Scripts, Inc., et al. (Acthar) Milberg Law Firm (2023)

• Expert Reports, Deposition Testimony

Woolsey Fire Damage to Malibu Hill and Prominence Treatment Center Facilities The Bernheim Law Firm (2022–2023)

Expert Report, Hearing Testimony

In the Matter of Woolsey Fire Damage to Biozyme Inc. The Bernheim Law Firm (2024)

• Expert Report

In re: Lipitor Antitrust Litigation
Cohen Milstein Sellers & Toll PLLC (2023–)

• Expert Reports, Deposition Testimonies, Hearing Testimony

In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation Kanner & Whiteley, L.L.C. and Golomb & Honik, P.C. (2021–)

• Expert Declarations, Deposition Testimonies

Zydus Worldwide DMCC v. Teva API Inc. (rotigotine) Locke Lord (2022–)

• Expert Report, Deposition Testimony

Peter Staley, et al. v. Gilead Sciences, Inc., et al. Hilliard & Shadowen, LLP (2021–2023)

• Expert Report, Deposition Testimony

In re: Novartis and Par Antitrust Litigation (Exforge)
Labaton Sucharow LLP (2021–2022)

• Expert Declaration, Deposition Testimony

In re: Ranbaxy Generic Drug Application Antitrust Litigation Lowey Dannenberg, P.C. (2020–2021)

• Expert Reports, Deposition Testimony

In re: Namenda Indirect Purchaser Antitrust Litigation Miller Law LLC (2020–2021)

• Expert Declarations, Deposition Testimony

In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation Zwerling, Schachter & Zwerling, LLP (2019–2021)

• Expert Declarations, Deposition Testimony, Hearing Testimony

In re: Zetia (Ezetimibe) Antitrust Litigation Miller Law LLC (2019–2021)

Expert Declarations, Deposition Testimony, Hearing Testimony

In re: Niaspan Antitrust Litigation Wexler Wallace, LLP (2018-)

• Expert Declarations, Deposition Testimony